About Namocell
Namocell is a Healthcare company based in Mountain View (United States) founded in 2014 by Jessica Zhou, and was acquired by Bio-Techne in June 2022. Single-cell sorting instruments are developed using microfluidic technology. Namocell offers products and services including Pala Cell Sorter, Hana Cell Sorter, RNAscope ISH Probes, and Simple Plex Immunoassays. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its competitors include NanoCellect Biomedical, Singulex and Cell Microsystems; 3 of its 3 listed competitors have raised funding.
Company details
Instruments for single-cell sorting were developed by Namocell, founded in 2014 and based in Mountain View, United States. The flagship product, Nami, employs microfluidics and fluorescence to enable gentle cell sorting directly into 96- and 384-well plates. Applications encompass single T-cell and B-cell receptor sequencing, circulating tumor cell isolation, single-cell RNADNA sequencing, monoclonal antibody development, cell line development, and transfection pool enrichment within the biotechnology sector.
- Headquarters Mountain View, United States
- Founders Jessica Zhou
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website namocell.com
- Social LinkedIn YouTube
- Acquired by Bio-Techne (Jun 2022)
- Investors
- Acquired byBio-Techne
(Jun 2022)
Products & Services of Namocell
Namocell offers a comprehensive portfolio of products and services, including Pala Cell Sorter, Hana Cell Sorter, RNAscope ISH Probes, and Simple Plex Immunoassays.
Device for fast and gentle single cell sorting and dispensing.
Instrument for simple single cell isolation in research applications.
Tools for spatial biology and molecular detection in diagnostics.
Kits for efficient protein analysis in immunoassays.
Apps and channels of Namocell
its YouTube channel Bio-Techne has 509 subscribers and 30 videos.
Videos from Namocell
The most watched videos on Namocell's YouTube channel, Bio-Techne (509 subscribers). Click a video to play it here.
More on Bio-Techne.
Investors in Namocell
Namocell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bio-Techne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States |
Investor details for Namocell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Namocell
3 people are tracked at Namocell (1 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Jessica Zhou | Co-Founder | Leadership |
Joe Marinaro | Midwest Regional Manager At Namocell | Team |
Hannah Roddy | Southwest Regional Manager | Team |
Complete people profiles for Namocell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Namocell
2 dated milestones of Namocell across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Namocell is founded.
- Exit Acquired by Bio-Techne.
Competitors of Namocell
Namocell has 3 listed competitors in our database, 3 of them funded. They include NanoCellect Biomedical, Singulex and Cell Microsystems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanocellect.com | 2009 | San Diego, United States | $78.15M | 84 | Develops flow cytometry and cell sorting technology | |
| singulex.com | 1997 | Alameda, United States | $140.94M | 236 | Single-molecule counting technology is developed for cardiovascular biomarker detection. | |
| cellmicrosystems.com | 2009 | Durham, United States | $19.1M | Developer of a technology to isolate and recover single cells for molecular analysis |
Detailed competitors of Namocell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Namocell (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Namocell
Complete news archive for Namocell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Namocell
Namocell was founded in 2014.
Namocell is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Instruments for single-cell sorting were developed by Namocell, founded in 2014 and based in Mountain View, United States. The flagship product, Nami, employs microfluidics and fluorescence to enable gentle cell sorting directly into 96- and 384-well plates. Applications encompass single T-cell and B-cell receptor sequencing, circulating tumor cell isolation, single-cell RNADNA sequencing, monoclonal antibody development, cell line development, and transfection pool enrichment within the biotechnology sector.
Namocell's top competitors include NanoCellect Biomedical, Singulex and Cell Microsystems.
Namocell offers Pala Cell Sorter, Hana Cell Sorter, RNAscope ISH Probes, and Simple Plex Immunoassays.
Namocell has 1 investor. Key investors include Bio-Techne.
Yes. Namocell was acquired by Bio-Techne in June 2022.